Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Hepatitis A Vaccine (Changchun) in Children
NCT04612634Phase 4Unknown
- Sponsor
- China National Biotec Group
- Start
- Nov 2020
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of altretamine + doxorubicin + vincristine + cytarabine + cyclophosphamide in hepatitis A (HAV) (3 arms), sponsored by China National Biotec Group. Primary endpoint: Antibody Seroconversion rate at 4 months. Status: unknown.
02
Drugs
altretamine + doxorubicin + vincristine + cytarabine + cyclophosphamide
03
Conditions
hepatitis A (HAV)
Beyond the preview
Go deeper on NCT04612634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04612634.